Badanie fazy II oceniające PF‑08634404, karboplatynę i etopozyd w leczeniu nieleczonych dorosłych z małokomórkowym rakiem płuca

First visit after joining the study

You will sign the consent form and allow the study staff to collect basic information such as medical history and current medications.

Baseline examinations will be performed, including blood tests, imaging studies, and other assessments needed to confirm eligibility.

Start of treatment cycles

The study medication PF-08634404 is given together with the chemotherapy drugs carboplatin and etoposide.

All three medicines are administered intravenous (through a vein). the protocol specifies a dose of 0 mg for each drug; the exact amount and schedule are defined by the study protocol.

The medicines are given on the first day of each treatment cycle; the length of each cycle and the total number of cycles are determined by the study protocol.

Monitoring during treatment

Regular blood tests are performed to check organ function and to detect possible side effects.

Imaging studies are repeated at defined intervals to evaluate the tumor response.

Any adverse events (side effects) are recorded and graded according to standard Criteria.

Completion of treatment

After the last scheduled treatment cycle, a final set of assessments is performed, including blood tests and imaging.

The study team evaluates the overall response of the disease and documents any lasting side effects.

Follow‑up visits

Periodic follow‑up visits are scheduled after treatment ends to monitor disease status and long‑term safety.

During these visits, additional blood tests and imaging may be performed as required by the protocol.